Introduction {#Sec1}
============

Although initially identified as targets in the treatment of asthma, recent findings have brought attention to leukotrienes (LTs) as potential mediators of cardiovascular disease \[[@CR1]\], such as atherosclerosis \[[@CR2]\], abdominal aortic aneurysms \[[@CR3]\], and aortic stenosis \[[@CR4]\]. Human coronary artery atherosclerotic lesions are a source of cysteinyl LTs (i.e., LTC~4~, D~4~, and E~4~) \[[@CR5]\], and urinary levels of LTE~4~ are increased in acute coronary syndromes \[[@CR6]\], implicating these mediators in coronary atherosclerosis and plaque instability. The notion of cysteinyl LTs as potential effectors of atherosclerosis has also received support from animal models showing beneficial effects on atherosclerosis burden \[[@CR7], [@CR8]\] and intimal hyperplasia \[[@CR9]\] by specific antagonists of the leukotriene CysLT~1~ receptor.

The cysteinyl LTs induce their action through G-protein-coupled receptors referred to as CysLT~1~ and CysLT~2~, and the existence of further subclasses of CysLT receptors also has been suggested \[[@CR10]\]. In human carotid atherosclerotic lesions, a 3-fold higher CysLT~1~ receptor expression compared with the CysLT~2~ receptor has been reported \[[@CR11]\], although the cellular localization of these receptors has not yet been resolved. The signaling through the CysLT~1~ receptor subtypes have been widely studied in the context of bronchoconstriction and asthma \[[@CR10]\]. Recently, the CysLT~1~ receptor antagonist montelukast was shown to be associated with a decreased risk of ischemic stroke and a decreased risk of myocardial infarction in males \[[@CR12]\]. Although the latter report provides a first indication of beneficial effects of clinically used anti-leukotriene drugs, the exact role of CysLT receptor signaling in atherosclerosis remains to be established.

In addition to being bronchoconstrictors, cysteinyl LTs are also potent vasoconstrictors in the human lung \[[@CR13]\]. Their role in the coronary vasculature, however, can be said to be contextually antithetical, as healthy human coronary arteries are unresponsive to cysteinyl LTs, but a contractile response to either LTC~4~ or LTD~4~ is observed in atherosclerotic coronaries \[[@CR14], [@CR15]\]. Although no previous study has addressed the mechanism for this differential sensitivity between healthy and atherosclerotic vessels, it is interesting to note that these leukotriene-induced contractions are inhibited by CysLT~1~ receptor antagonists \[[@CR14]\]. The latter observation is, however, in contrast to the dominant CysLT~2~ receptor expression in human coronary artery smooth muscle cells (SMCs) \[[@CR16]\].

With the notion in mind that a local production of cysteinyl LTs within the atherosclerotic lesion \[[@CR5]\] could potentially activate CysLT receptors within the vascular wall, we engaged in this study with the hypothesis that the inflammatory environment of atherosclerosis could lead to an upregulation of CysLT~1~ receptors on vascular SMCs. Here, we have investigated this idea, with the aim to quantify and describe the nature of the increased CysLT~1~ signaling. Further, we have explored the potential downstream effects of this phenomenon on both intracellular signaling and gene expression in vascular SMCs in an effort to link CysLT~1~ receptor signaling to atherogenic properties of SMCs in the context of inflammation and leukotriene stimulation.

Methods {#Sec2}
=======

Cell culture {#Sec3}
------------

Human coronary artery SMC purchased from Clonetics (Cambrex Bio Science, Walkersville, MD, USA) were cultured in SmGM2 kit medium as previously described \[[@CR17]\] and harvested for experiments between passages 5 and 8. Cells were seeded in six-well plates (10^5^ cells/well) containing SmGM2 48 h before the respective treatment, which was replaced with Dulbecco's modified Eagle's medium supplemented with 2 % fetal calf serum (starvation medium) 24 h before experiments. Subsequently, cells were incubated in the absence or presence of lipopolysaccharide (LPS; from Sigma, 10 μg/mL), interleukin-6 (IL-6; from Peprotech, 20 ng/mL), interferon-γ (IFN-γ; from Peprotech, 20 ng/mL), or tumor necrosis factor-α (TNF-α; from Peprotech, 10 ng/mL). Duration of treatment was experiment-dependent, as described in detail below. Cells were treated with various substances across experiments, including LTC~4~, LTD~4~, and LTE~4~ (from Cayman Chem, Ann Arbor, MI, USA; 1 μM), the CysLT~1~ receptor antagonist MK571 (from Cayman; 1 μM), ethylene glycol tetraacetic acid (EGTA; from Sigma, 5 mM), and 1,2-bis(2-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-AM; from Invitrogen, 10 μM).

Immunostainings {#Sec4}
---------------

Atherosclerotic vascular tissue was collected from eight patients undergoing carotid endarterectomy. All experiments were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and were approved by the local ethics committee (reference number 02/147). All persons gave their informed consent prior to their inclusion in the study. Immunofluorescent stainings were performed on acetone-fixed frozen sections of carotid endarterectomies and on human coronary artery SMCs cultured in LabTek slides after fixation and permeabilization with acetone--methanol. Rabbit anti-human CysLT~1~ receptor (from Cayman Chem) and mouse anti-human α-smooth muscle actin (from DAKO) were used as primary antibodies. Isotype-specific either DyLight 594 or DyLight 488-conjugated secondary antibodies (from Vector) were used, and the nuclei were counterstained with 4′, 6-diamino-2-phenylindol (DAPI; Vector). Images were captured with confocal microscope Leica DMI.

Calcium signaling experiments {#Sec5}
-----------------------------

SMCs incubated for 48 h in the absence or presence of LPS (10 μg/mL) were washed and loaded with the fluorescent Ca^2+^ indicator fluo-3. The cells were subsequently stimulated with LTC~4~ (1 μM, 30 min at room temperature) in either Tyrode's solution (composition, millimolars: NaCl 121, KCl 5.0, NaHCO~3~ 24, CaCl~2~ 0.5, MgCl~2~ 0.4, NaH~2~PO~4~ 0.4, EDTA0.1, and glucose 5.5) gassed with 5 % CO~2~ in O~2~ or Tyrode's solution containing the CysLT~1~ receptor antagonist MK571 (1 μM). Changes in \[Ca^2+^\] were recorded using a BioRad MRC 1024 confocal microscopy unit attached to a Nikon Diaphot 200 inverted microscope with a Nikon Plan Apo ×20 or ×60 oil immersion objective (N.A.1.3), as previously described \[[@CR18]\].

RNA extraction, cDNA synthesis, and TaqMan real-time PCR {#Sec6}
--------------------------------------------------------

Total RNA was extracted using RNeasy Mini kit (from Qiagen, Hilden, Germany) with an on-column DNase digestion step. RNA quantity was assessed using a Nanodrop ND-1000 microvolume spectrophotometer (Thermo Fisher Scientific), and RNA quality was assessed by a Bioanalyzer capillary electrophoresis system (Agilent Technologies, Palo Alto, CA, USA). First-strand cDNA was synthesized using Superscript II (Invitrogen, Carlsbad, CA, USA) with random hexamers according to the manufacturer's instructions. Quantitative TaqMan PCR was performed on a 7900HT Fast Real-Time PCR system (Applied Biosystems) with primer/probe pairs that were obtained using Assay-on-demand™ from Applied Biosystems for human CysLT~1~ (Hs00272624_s1) and Plasminogen Activator Inhibitor 2 (PAI-2/SERPIN B2; Hs01010736_m1). Levels of mRNA were normalized to expression levels of cyclophilin A (Hs99999904_m1), which previously has been determined as an appropriate housekeeping gene in these cells \[[@CR17]\]

Microarray analysis {#Sec7}
-------------------

Microarray analysis experiments were performed on RNA derived from three separate SMC culture experiments, using either Agilent one-color whole human genome (44 K) kit (Agilent Technologies, Redwood City, CA, USA; *n* = 2) or the Affymetrix Human Genome U133 Plus 2.0 array (*n* = 1). Microarrays were analyzed with the Agilent high-resolution microarray scanner. Data were subsequently uploaded to GeneSpring GX10 (Agilent technologies) and analyzed using advanced analysis workflow for the Agilent one-color arrays. The set of data was normalized according to recommendations by GeneSpring for one-color arrays. (<http://www.chem.agilent.com/cag/bsp/products/gsgx/manuals/GeneSpring-manual.pdf>). Variability between chips was accounted for by applying a shift to the 75th percentile (dividing all measured signals by a 75th percentile value). Per-gene normalization was performed by bringing the baseline to the median of all samples. Probe sets were firstly filtered by confidence of detection, where genes that were not confidently detected in any sample were excluded from further analysis. Further filtering based on expression discarded any genes where less than 100 % of samples in either the relapse or diagnosis condition had expression values below the 20th percentile. The most differentially expressed genes, defined as those with an uncorrected *P* value of \<0.05 and demonstrating a fold change in expression of 2.0 or greater, were selected for analysis. The list of 90 genes generated was subsequently compared to data from the Affymetrix arrays, and the genes of interest were verified in terms of direction of regulation. Genes meeting all these criteria are presented in Table [1](#Tab1){ref-type="table"}. The 45 genes listed were submitted to Ingenuity® pathway analysis for prediction of canonical pathways and functional gene networks affected by the significant differential expression of these genes.Table 1Most significantly differentially expressed genes in response to LTC~4~ (1 μM) in LPS-primed human coronary artery SMCs (sorted by fold change)Gene IDProbe IDGene nameMean fold changeDirection*P* valueCSF3A_23_P501754Colony stimulating factor 315.88Up0.04128IL24A_23_P51951Interleukin 2415.11Up0.04918SERPINB2A_23_P153185Serine proteinase inhibitor 2 (plasminogen activator inhibitor 2)5.46Up0.03882NEFMA_24_P264832Neurofilament medium polypeptide4.89Up0.01537GJA1A_23_P93591Gap junction protein. Alpha 14.74Up0.00931IL1AA_23_P72096Interleukin 1 alpha4.15Up0.01096CXCR4A_23_P102000Chemokine (C-X-C motif) receptor 43.94Up0.00170TFPI2A_24_P95070Tissue factor pathway inhibitor 23.90Up0.02599CCND1A_24_P124550Cyclin D13.28Up0.04980CXCL3A_24_P183150Chemokine (C-X-C motif) ligand 33.27Up0.02149ABCG1A_23_P166297ATP-binding cassette. Sub-family G. Member 13.03Up0.00178HAS1A_23_P27400Hyaluronan synthase 12.85Up0.03572MMP3A_23_P161698Matrix metallopeptidase 32.70Up0.01282PITPNC1A_24_P772103Phosphatidylinositol transfer protein. Cytoplasmic 12.55Up0.03758KITLGA_23_P204654KIT ligand2.49Up0.00730FUBP3A_23_P435833Far upstream element (FUSE) binding protein 32.46Up0.00619NPTX1A_23_P124905Neuronal pentraxin I2.45Up0.00504PCSK1A_23_P213508Proprotein convertase subtilisin/kexin type 12.41Up0.04376ADSSA_23_P859Adenylosuccinate synthase2.40Up0.01023TFPI2A_23_P393620Tissue factor pathway inhibitor 22.38Up0.01401NPR3A_23_P327451Natriuretic peptide receptor C/guanylate cyclase C2.33Up0.01309SPRED1A_23_P54460Sprouty-related. Evh1 domain containing 12.30Up0.02536PITPNC1A_23_P84189Phosphatidylinositol transfer protein. Cytoplasmic 12.29Up0.01626NKAIN1A_23_P51376Na+/K+ transporting ATPase interacting 12.26Up0.02838SOCS4A_24_P90637Suppressor of cytokine signaling 42.23Up0.00918TMTC3A_24_P944222Transmembrane and tetratricopeptide repeat containing 32.22Up0.04956CACNG8A_32_P61693Calcium channel. Voltage-dependent. Gamma subunit 82.19Up0.00480RRN3A_23_P206877RNA polymerase I-specific transcription initiation factor RRN32.15Up0.00613APOBEC3FA_23_P369966Apolipoprotein B mRNA editing enzyme. Catalytic polypeptide-like 3F2.12Up0.03633NFE2L3A_24_P136653Nuclear factor (erythroid-derived 2)-like 32.08Up0.00912MYH11A_24_P70183Myosin heavy chain 11 (smooth muscle)10.44Down0.02218MYH11A_23_P206920Myosin heavy chain 11 (smooth muscle)9.66Down0.01751SCRG1A_23_P167159Stimulator of chondrogenesis 14.73Down0.01807TPD52L1A_23_P31143Tumor protein D52-like 14.64Down0.01830CARD9A_23_P500433Caspase recruitment domain family. Member 93.54Down0.00009CLIC3A_23_P254654Chloride intracellular channel 33.53Down0.00765KRT7A_23_P381945Keratin 73.37Down0.03569PCK2A_23_P128817Phosphoenolpyruvate carboxykinase 2 (mitochondrial)2.66Down0.02696CTAGE1A_24_P124805Cutaneous T cell lymphoma-associated antigen 12.57Down0.01412GLI1A_23_P105251GLI family zinc finger 12.56Down0.01105SLC1A7A_23_P325562Solute carrier family 1. Member 72.53Down0.00758TGM1A_23_P65618Transglutaminase 12.45Down0.00203IL17RDA_32_P188860Interleukin 17 receptor D2.39Down0.01570ZNF467A_23_P59470Zinc finger protein 4672.19Down0.00619LIMS2A_23_P142796LIM and senescent cell antigen-like domains 22.05Down0.01940Note that some genes may be listed twice due to significant differences detected by independent probes

ELISA {#Sec8}
-----

PAI-2 ELISA was carried out on supernatants from untreated SMCs and SMCs treated LTC~4~ (1 μM) for 24 h using IMUBIND® PAI-2 ELISA kit (from American Diagnostica GmBH, Pfungstadt, Germany) according to manufacturer's protocol.

Data analysis {#Sec9}
-------------

All results are expressed as mean±SE. Statistically significant differences were determined by either a Student's *t* test (for pair-wise comparisons) or a one-way analysis of variances, followed by Holm--Sidak post hoc test, for multiple comparisons, using Sigma Stat software. A *P* value of less than 0.05 was considered significant.

Results {#Sec10}
=======

CysLT~1~ receptor expression on vascular SMC {#Sec11}
--------------------------------------------

Immunohistochemical staining showed colocalization of the CysLT~1~ receptor protein with markers for SMC (α-smooth muscle actin) in human atherosclerotic lesions (Fig. [1](#Fig1){ref-type="fig"}). In human coronary artery SMCs, the transcriptional levels of the CysLT~1~ receptor were time-dependently increased by LPS, IL-6, and IFN-γ (Fig. [2](#Fig2){ref-type="fig"}). Fluorescent immunostainings revealed a predominantly perinuclear localization of the CysLT~1~ receptor in human coronary artery SMCs compared with α-smooth muscle actin, which stained positive in the whole cytoplasm (Fig. [3](#Fig3){ref-type="fig"}). The CysLT~1~ receptor in some cases demonstrated nuclear inclusions, as indicated by arrows in Fig. [3](#Fig3){ref-type="fig"}.Fig. 1CysLT~1~ receptor expression in human atherosclerotic lesions. Representative immunofluorescent staining of human atherosclerotic plaques from carotid artery showing colocalization of the CysLT~1~ with α-smooth muscle actin-positive vascular smooth muscle cells. Original magnification, ×40Fig. 2CysLT~1~ receptor expression in human coronary artery smooth muscle cells is upregulated by pro-inflammatory stimuli. Real-time quantitative TaqMan RT-PCR for CysLT receptor mRNA in SMCs incubated in the absence and presence of LPS (10 μg/mL) for 1, 4, and 8 h (**a**) and IL-6 (20 ng/mL), TNF-α (10 ng/mL), or IFN-γ (20 ng/mL) for either 8 h (**b**) or 24 h (**c**). Results are expressed as fold increase compared with untreated cells (*n* = 3--5). \**P* \< 0.05 vs. time-matched controlFig. 3Perinuclear CysLT~1~ receptor expression in human coronary artery smooth muscle cells. Fluorescent labeling of CysLT~1~ receptor protein (DyLight 594 *red* chromogen) and α~SM~-actin (DyLight 488 *green* chromogen) in SMCs. Nuclei were stained with DAPI. *Arrows* indicate nuclear inclusions. Original magnification, ×63

LTC~4~-induced nuclear calcium signaling in vascular SMCs {#Sec12}
---------------------------------------------------------

To evaluate whether CysLT~1~ receptors expressed on vascular SMC were functional, calcium changes in human coronary artery SMC were studied using the fluorescent Ca^2+^ indicator fluo-3 (Fig. [4a](#Fig4){ref-type="fig"}). LTC~4~ induced a dose-dependent increase in intracellular calcium, which was predominantly located in the nucleus (Fig. [4b](#Fig4){ref-type="fig"}). The LTC~4~-induced calcium increase was significantly higher in LPS-treated cells compared with untreated cells (Fig. [4c](#Fig4){ref-type="fig"}). In LPS-treated cells, the LTC~4~-induced increase in nuclear calcium was significantly inhibited by the CysLT~1~ receptor antagonist MK571 (Fig. [4c](#Fig4){ref-type="fig"}). The time course of the LTC~4~-induced calcium increase in the nuclear and cytosolic compartments is shown in Fig. [4d](#Fig4){ref-type="fig"}. The increase in nuclear calcium preceded the increase in cytosolic calcium (Fig. [4d](#Fig4){ref-type="fig"}).Fig. 4LTC~4~-induced calcium signaling in human coronary artery SMC. **a** Representative micrographs of Ca^2+^ fluorescence in the absence and presence of LTC~4~ (1 μM). **b** Concentration--response curves for Ca^2+^ fluorescence in nuclei (*blue symbols*) and cytosol (*black symbols*) of SMCs incubated for 48 h in the presence of LPS (10 μg/ml). **c** Ca^2+^ fluorescence in nuclei (*blue bars*) and cytosol (*black bars*) of SMCs incubated for 48 h in the absence (control) or presence of LPS (10 μg/ml) prior to stimulation with LTC~4~ (1 μM, 30 min). **d** The time course of the LTC~4~-induced calcium increase shows that the increase in nuclear calcium (*blue symbols*) preceded the increase in cytosolic calcium (*black symbols*). \**P* \< 0.05 vs. controls, ^*\#*^*P* \< 0.05 vs Nuclear Ca^2+^

LTC~4~-induced gene expression in vascular SMCs {#Sec13}
-----------------------------------------------

The genes most significantly differentially expressed in response to LTC~4~ (1 μM) in LPS-primed human coronary artery SMCs are presented in Table [1](#Tab1){ref-type="table"}. PAI-2 (SERPIN B2), a member of the serine protease inhibitor superfamily, presented as one of the most significantly upregulated genes in the microarray analysis. This finding was confirmed by quantitative PCR (Fig. [5a](#Fig5){ref-type="fig"}), and in addition, increased PAI-2 protein levels were detected in the supernatant derived from LTC~4~-stimulated human coronary artery SMCs, compared with unstimulated cells (Fig. [5b](#Fig5){ref-type="fig"}). The increased mRNA levels of PAI-2 induced by LTC~4~ (1 μM) were mimicked by LTD~4~ (1 μM) but not LTE~4~ (1 μM) and significantly inhibited by the CysLT~1~ receptor antagonist MK 571 (1 μM; Fig. [5a](#Fig5){ref-type="fig"}). In addition, the LTC~4~-induced increase in PAI-2 mRNA was abolished by the removal of intra- and extracellular calcium, through experiments performed in the presence of BAPTA-AM and EGTA (Fig. [5c](#Fig5){ref-type="fig"}).Fig. 5LTC~4~-induced upregulation of PAI-2 in human coronary artery SMC. **a** Real-time quantitative RT-PCR for PAI-2 mRNA in human coronary artery SMC incubated in the absence and presence of LTC~4~, LTD~4~ or LTE~4~ (1 μM) for 24 h. In some experiments, cells were pretreated with the CysLT~1~ receptor antagonist MK571 (1 μM) for 1 h before addition of LTC~4~. \**P* \< 0.05 vs. non-LTC~4~ stimulated Contr (*n* = 3--6). **b** PAI-2 concentrations in supernatants from human coronary artery SMC incubated 24 h in the absence (*Contr*) or presence of LTC~4~ (1 μM). \**P* \< 0.05 vs. Contr (*n* = 7). **c** Increase in PAI-2 mRNA levels induced by LTC~4~ (1 μM) in human coronary artery SMC incubated in the absence (*Contr*) or presence of either BAPTA-AM or EGTA. \**P* \< 0.05 vs. Contr (*n* = 3--6)

Ingenuity pathway analysis identified several functional gene networks predicted to be significantly affected by LTC~4~ stimulation as based on the 45 genes determined to be differentially expressed through our microarray analysis (Table [1](#Tab1){ref-type="table"}). The highest-scoring network (with a score of 35, equating to a fishers' exact test score of 1 × 10^−35^) containing 15 genes from Table [1](#Tab1){ref-type="table"} is suggested to be implicated in cellular movement and hematopoietic system function and development. An outline of the network is shown in Supplementary Fig. [1](#MOESM1){ref-type="media"}.

Discussion {#Sec14}
==========

The results of the present study showed an upregulation of predominantly perinuclear CysLT~1~ receptors in vascular SMCs under inflammatory conditions which was associated with increased nuclear calcium signaling and changes in gene expression. Taken together, these findings suggest a role of nuclear CysLT~1~ receptor signaling in vascular SMCs inducing gene expression patterns associated with atherosclerosis.

Previous studies have suggested a dominant expression of the leukotriene CysLT~2~ receptor subtype in human coronary arteries \[[@CR16]\]. In the present study, priming of vascular SMCs with LPS upregulated CysLT~1~ receptor mRNA and enhanced LTC~4~-induced effects. Similar findings have been reported in endothelial cells, which under resting conditions exhibit a dominant CysLT~2~ receptor, but in which prolonged exposure to LPS or pro-inflammatory cytokines upregulate CysLT~1~ receptor expression \[[@CR19]\]. In the present study, CysLT~1~ receptor expression was also upregulated in SMCs by IL-6 and by prolonged exposure to IFN-γ. Taken together, these observations suggest that a pro-inflammatory environment, such as atherosclerosis, may induce CysLT~1~ receptor expression within the vascular wall. In support of the latter notion, it has been shown that LTC~4~ induces contractions of atherosclerotic but not healthy coronary arteries \[[@CR14], [@CR15]\] and that CysLT~1~ receptor signaling, but not CysLT~2~ receptor signaling, is coupled to vasoconstriction in isolated systemic vessels \[[@CR20]\]. LTC~4~ has also been associated with SMC proliferation and the shift of SMCs into a synthetic phenotype \[[@CR21]\], which is in line with findings that CysLT~1~ receptor antagonism inhibits intimal hyperplasia after vascular injury in mice \[[@CR9]\].

The present study is the first demonstration of a perinuclear localization of functional CysLT~1~ receptors in vascular SMCs and a leukotriene-induced nuclear calcium signaling in these cells. These findings are nevertheless consistent with other G-protein-coupled receptors in vascular SMCs. For example, the ET~A~ endothelin receptor and the AT~1~ angiotensin II receptor exhibit a perinuclear localization in vascular SMCs coupled to nuclear calcium signaling \[[@CR22]--[@CR24]\]. In addition, we have recently demonstrated a perinuclear localization of the CysLT~1~ receptor in valvular interstitial cells derived from human aortic valves \[[@CR4]\], corroborating prior observations of CysLT~1~ receptor expression at the outer nuclear membrane in intestinal epithelial cells \[[@CR25]\]. In both of these cell types, leukotriene stimulation induces an increase in nuclear calcium \[[@CR4], [@CR25]\]. The present study extends those findings by demonstrating an enhanced nuclear calcium increase in response to LTC~4~ after priming of cells with LPS and that the increase in nuclear calcium preceded the increase in cytosolic calcium. Whereas the present study cannot definitely conclude whether the subcellular CysLT~1~ receptor localization represents an internalization process, previous studies support a translocation of CysLT~1~ receptors between different cellular compartments, including nuclear inclusions \[[@CR26]\].

Nuclear calcium is a key regulator of gene expression \[[@CR27]\], and in line with this notion, LTC~4~ induced significant changes in expression of several genes in the present study. Of particular interest was the appearance of PAI-2 as one of the most significantly upregulated genes in the microarray analysis. This was confirmed with qPCR analysis, and ELISA measures in addition showed that PAI-2 protein secretion from human coronary artery SMCs was increased by LTC~4~ stimulation. PAI-1 and PAI-2 are members of the serine proteinase inhibitor family and act as important inhibitors of fibrinolysis by interfering with the plasminogen system. PAI-1 is induced by atherogenic stimuli in vascular SMCs and may participate in cell growth and matrix degradation associated with atherosclerosis \[[@CR28]\]. In addition, using cDNA representational difference analysis, PAI-2 has previously been identified as one of the most differentially expressed genes in atherosclerotic lesions compared with normal vessels, with elevated PAI-2 expression preferentially observed in unstable carotid plaques \[[@CR29]\]. In addition, another study using serial analysis of gene expression in human vascular SMCs also identified PAI-2 as one of the most upregulated genes in response to conditioned media derived from macrophages activated by oxidized low-density lipoprotein \[[@CR30]\]. Finally, immunohistochemical analysis of human atherosclerotic lesions has also confirmed that vascular SMCs stain positive for PAI-2 \[[@CR29], [@CR30]\]. In addition to acting as a plasminogen activator inhibitor, PAI-2 may serve as a regulator of Th1 immune responses through the modulation of cytokine-induced responses \[[@CR31]\]. Furthermore, PAI-2 may be associated with the process of wound healing post-plaque rupture \[[@CR29]\].

The LTC~4~-induced increase in PAI-2 mRNA was abolished when experiments were performed in the presence of calcium chelators, suggesting a calcium dependent upregulation of PAI-2. The latter notion is supported by previous studies showing that angiotensin II is a potent inducer of PAI-2 in vascular SMCs through the AT~1~ receptor \[[@CR32]\], which is in line with a perinuclear AT~1~ receptor localization and an EGTA-sensitive nuclear calcium signaling induced by angiotensin II \[[@CR33]\].

Ingenuity pathway analysis revealed a significant number of LTC~4~-upregulated genes to be implicated in a functional gene network linked to hematopoietic system function and cellular movement. Of note in this network was the involvement of cAMP response element binding protein (CREB), a transcription factor and member of the leucine zipper family of DNA binding proteins, which is known to be activated by nuclear calcium \[[@CR27]\]. Furthermore, the PAI-2 gene promoter region contains a binding site for CREB (−1,319 bp), and this transcription factor has been shown to be associated with the induction of PAI-2 expression \[[@CR34]\]. Taken together, these findings suggest that LTC~4~-induced changes in gene expression may be induced through an increase in nuclear calcium leading to CREB activation. However, the pathway analysis also revealed other pathways that may be involved in LTC~4~-induced gene expression, such as the NF-κB signaling pathway which has been previously shown to be activated after CysLT~1~ receptor ligation in leukocytes \[[@CR10]\].

In summary, we have shown that pro-inflammatory stimulation of vascular SMCs enhances perinuclear CysLT~1~ receptor expression coupled to nuclear calcium signaling and results in changes in gene expression, such as upregulation of PAI-2. Since cysteinyl-LT production is increased in atherosclerosis \[[@CR5]\] and acute coronary syndromes \[[@CR6]\], an altered vascular sensitivity to leukotriene-induced SMC gene expression secretion may further enhance the inflammatory response. As such, targeting CysLT~1~ receptors could potentially be of therapeutic interest in atherosclerosis.
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